US › Healthcare

Tenaya Therapeutics Inc (TNYA)

US · Healthcare · Biotechnology

$0.38-6.78%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$1.1M

Net profit

$-43.4M

EPS

$-0.09

EPS estimate

$-0.08

Net margin

-3,909.3%

EPS came in at -0.09 against a street estimate of -0.08 — a miss of 12.5%.

Key statistics

Market cap

$130.1M

Forward P/E

0.0

P/B

2.14

Book value

$0.31

EPS (TTM)

$-0.56

52-week high

$2.20

52-week low

$0.52

50-day MA

$0.67

200-day MA

$0.74

Beta

2.88

Analyst view

Analysts rate Tenaya Therapeutics Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $3.20.

Shareholding

Insiders

0.48%

Institutions

48.86%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.17%
Millennium Management LLC	2.87%
Citadel Advisors Llc	2.04%
Renaissance Technologies Corp	1.91%
BlackRock Inc	1.79%
Empery Asset Management, LP	1.72%
Marshall Wace Asset Management Ltd	1.56%
GSA Capital Partners LLP	1.19%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tenaya Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.